Vemurafenib (INN marketed as Zelboraf) is a B-Raf enzyme inhibitor developed by Plexxikon (now part of the Daiichi Sankyo group) and Genentech for the treatment of late-stage melanoma. The name vemurafenib comes from V600E mutated BRAF inhibition.Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17 2011 making it the first drug designed using fragment-based lead discovery to gain regulatory approval.
This page contains content from the copyrighted Wikipedia article "Vemurafenib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
